Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

- Company to be Featured on Oct 25, 2007 -

SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Windhover Information has chosen the company's lead compound, VIA-2291, as one of the top ten most interesting cardiovascular projects available for partnering. VIA will be featured at Windhover Information's 2nd Annual Therapeutic Area Partnerships conference and Lawrence Cohen, Ph.D., chief executive officer and president of the company, will be providing more details about VIA-2291 at the meeting on October 25 at 2 p.m. Eastern Time in Philadelphia.

Windhover Information provides critical commentary, analysis and data to the biotech, pharmaceutical, and medical device and diagnostic industries. Its editorial and research staff, including the publishers of In Vivo and Startup, have chosen the top ten best compounds for licensing in each of four disease areas based on the following criteria: size of market, history of the molecule and drug, strength of the underlying science, diversity of potential indications, overall company strength and availability of multi-partnering opportunities.

"We are honored and delighted that VIA-2291 has been identified as one of the top cardiovascular drugs by the knowledgeable editorial and research staffs of the Windhover organization," said Dr. Cohen.

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversible inhibitor of 5-L
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 The Kidney Cancer ... of its monthly news magazine, Kidney Cancer News. , ... presence on a website maintained by an international news organization. ... immediate increase in viewers.” , This month’s program highlights news ... tumors analyzed in a recent study. Kidney Cancer News ...
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Computing researchers at Houston,s Rice University and electronics ... announced the formation of a $2.6-million Institute for ... at 4 million Singapore dollars, aims to slash ... -- special-purpose computer chips that power everything from ...
... Presented at the 12th World Conference on Lung ... 4 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI ... that identifies,develops and commercializes differentiated products for patients ... two cohorts of,the Phase I part of a ...
... 4 The Cytokine Institute (TCI), a Los,Angeles-based ... the opening of a new office in the ... measures and analyzes the effects of,chemical and toxic ... Boston-based consulting arm, Green Reach Consulting, TCI now ...
Cached Biology Technology:Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 2YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 4YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 5Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2
(Date:7/31/2014)... make a rational choice to be liberal or conservative? ... a matter of genetics?, Two political scientists from the ... say that neither conscious decision-making nor parental upbringing fully ... right. , A growing body of evidence shows that ... of political differences, the researchers say in the latest ...
(Date:7/31/2014)... the U.S. surgeon general issued a 101-page report about ... University published a paper breaking new ground on how ... responds when exposed to ultraviolet (UV) light. , The ... UV rays found in sunlight. This damage can lead ... , "Our paper advances foundational knowledge about how ...
(Date:7/31/2014)... Florida State University researcher found that bacteria in the ... of the oil released during the Deepwater Horizon spill ... most toxic contaminants. , In two new studies conducted ... found a species of bacteria called Colwellia ... and xylene compounds that were released as part of ...
Breaking Biology News(10 mins):Scientists find growing consensus: Political attitudes derive from body and mind 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... This press release is available in French ... a whole lot safer for consumers, thanks to Concordia University ... substances in dairy and other products. "Even though Canada ... antibiotics in cows, until now there were no methods or ...
... basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist ... at the Institut de recherches cliniques de Montral (IRCM), and ... patents awarded to the institute and covering different uses of ... Schiller,s laboratory at the IRCM. A total of ...
... OAK RIDGE, Tenn. -- A tree outside Oak Ridge ... inspiration for a discovery that may ultimately lead to ... more. Just as a breeze causes leaves, branches ... the molecular level perform hundreds of chemical processes that ...
Cached Biology News:Discovery of therapeutic peptides affecting mitochondria 2ORNL fundamental discovery casts enzymes in new light 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: